Keeps Biopharma Inc. (KOSDAQ:256940)
South Korea · Delayed Price · Currency is KRW 8,510.00
-370.00 (-4.17%)
At close: Feb 6, 2026
Keeps Biopharma Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | -28.35 | 1,113 | 3,930 | -11,375 | -15,317 | -2,406 |
Depreciation & Amortization | 3,192 | 2,582 | 1,442 | 993.33 | 812.4 | 604.28 |
Loss (Gain) From Sale of Assets | 25.69 | -24.15 | 77.46 | -52.48 | -19.15 | 82.9 |
Asset Writedown & Restructuring Costs | 383.84 | 383.84 | - | - | - | - |
Loss (Gain) From Sale of Investments | -227.89 | -847.49 | -1,077 | 177.95 | 2,519 | -2,871 |
Loss (Gain) on Equity Investments | 1,816 | 1,609 | -4,930 | 3,998 | 3,081 | 2,184 |
Stock-Based Compensation | - | - | 269.1 | 509.97 | 1,458 | 59.53 |
Provision & Write-off of Bad Debts | -285.69 | -1,343 | 70.84 | 912.84 | 2,926 | 139.34 |
Other Operating Activities | -3,592 | 5,258 | 5,255 | 565.12 | -2,073 | 2,959 |
Change in Accounts Receivable | -1,203 | -963.41 | -622.46 | 561.76 | -1,447 | -4,193 |
Change in Inventory | -7,998 | -4,816 | -696.77 | 0.6 | -1,997 | 3,150 |
Change in Accounts Payable | -2,378 | -1,090 | 1,224 | -138.22 | 611.5 | -647.04 |
Change in Other Net Operating Assets | 1,146 | 2,945 | -4,999 | 2,980 | 1,066 | -798.88 |
Operating Cash Flow | -9,149 | 4,808 | -57.13 | -866.26 | -8,380 | -1,737 |
Capital Expenditures | -6,461 | -6,596 | -990.97 | -95.85 | -90.75 | -1,043 |
Sale of Property, Plant & Equipment | -969.82 | 27.18 | 24.18 | 30.31 | 38.3 | 177.47 |
Cash Acquisitions | -23,152 | -17,812 | -26,610 | - | - | - |
Sale (Purchase) of Intangibles | -2,502 | -104.49 | -79.79 | -33.96 | -32.2 | -649.38 |
Investment in Securities | 418.12 | 100.66 | 682.22 | -3,199 | -11,484 | -5,094 |
Other Investing Activities | 196.22 | 456.64 | 992.3 | -4,784 | -88.42 | -27.79 |
Investing Cash Flow | -33,977 | -22,275 | -27,591 | -9,427 | -14,276 | -9,531 |
Short-Term Debt Issued | - | 500 | 19,000 | - | 3,000 | 14,000 |
Long-Term Debt Issued | - | 12,012 | 3,000 | - | 32,000 | 28,000 |
Total Debt Issued | 53,028 | 12,512 | 22,000 | - | 35,000 | 42,000 |
Short-Term Debt Repaid | - | -6,000 | -13,000 | - | -7,000 | -10,000 |
Long-Term Debt Repaid | - | -6,234 | -248.51 | -3,327 | -330.69 | -620.41 |
Total Debt Repaid | -3,132 | -12,233 | -13,249 | -3,327 | -7,331 | -10,620 |
Net Debt Issued (Repaid) | 49,896 | 278.15 | 8,751 | -3,327 | 27,669 | 31,380 |
Issuance of Common Stock | 1,199 | - | - | 353.55 | 398.18 | 6,133 |
Other Financing Activities | -2,381 | 31,649 | -600 | -298 | -35.68 | 1,178 |
Financing Cash Flow | 48,714 | 31,927 | 8,151 | -3,272 | 28,032 | 38,690 |
Foreign Exchange Rate Adjustments | 251.06 | 210.67 | -21.75 | -6.82 | 673.45 | -677.29 |
Net Cash Flow | 5,839 | 14,671 | -19,519 | -13,572 | 6,049 | 26,744 |
Free Cash Flow | -15,610 | -1,787 | -1,048 | -962.12 | -8,471 | -2,780 |
Free Cash Flow Margin | -9.89% | -1.40% | -1.14% | -6.58% | -198.82% | -18.27% |
Free Cash Flow Per Share | -809.50 | -94.64 | -55.71 | -51.34 | -489.19 | -189.82 |
Cash Interest Paid | 1,334 | 1,326 | 1,360 | - | 79.71 | 153.18 |
Cash Income Tax Paid | 2,252 | 13.85 | 14.57 | 137.28 | 43.29 | -3.69 |
Levered Free Cash Flow | -15,768 | 21,084 | -12,423 | 23.1 | -9,364 | -7,098 |
Unlevered Free Cash Flow | -11,638 | 23,416 | -11,154 | 607.29 | -8,308 | -6,057 |
Change in Working Capital | -10,433 | -3,924 | -5,095 | 3,405 | -1,766 | -2,489 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.